PF-04518600 for Cancer

"This research effort is no longer recruiting participants, having been posted first on 11th September 2015 and last updated on 21st July 2022. Patients searching for other clinical trials should be aware that there are 2468 cancer-related studies currently active as well as 114 involving PF-04518600 which require volunteers."

"A search of clinicaltrials.gov reveals that the drug PF-04518600 is present in 114 active studies across 1024 cities and 52 nations. The trail for this medication was first initiated by EMD Serono Research & Development Institute, Inc. back in 2014; it successfully completed Phase 2 trials with 204 participants involved. 56 additional experiments have been conducted since then."

"This clinical trial is assessing its primary outcome, the Objective Response - Number of Participants With Objective Response, during an 8-week period for Combination A to D and a 4-week period for Combination F. Secondary outcomes include examining anti-drug antibody (ADA) levels of avelumab (MSB0010718C), trough plasma concentration at the end of PF-05082566 doses, as well as maximum concentrations of PF-05082566 in blood samples."

"According to a clinicaltrials.gov review, the date of this medical trial's last update was July 21st 2022 and it is no longer in need of participants. Nevertheless, there are presently 2,582 other trials actively recruiting patients."

"PF-04518600 was first tested in 2014 at the Port Macquarie Base Hospital, and there have been 56 concluded studies. There are currently 114 ongoing trials being conducted from multiple sites, notably including New york City."

"At this moment in time, 62 clinical trial sites across the USA are recruiting patients. These locations span from New york to Goldsboro and Vista as well as additional unspecified areas. Prospective participants should endeavour to choose a nearby site so as to reduce commuting obligations."